Sino Biopharmaceutical (HKSE:01177) Total Liabilities : HK$27,820 Mil (As of Dec. 2023)

View and export this data going back to 2003. Start your Free Trial

What is Sino Biopharmaceutical Total Liabilities?

Sino Biopharmaceutical's Total Liabilities for the quarter that ended in Dec. 2023 was HK$27,820 Mil.

Sino Biopharmaceutical's quarterly Total Liabilities increased from Dec. 2022 (HK$29,169.41 Mil) to Jun. 2023 (HK$31,918.79 Mil) but then declined from Jun. 2023 (HK$31,918.79 Mil) to Dec. 2023 (HK$27,820.12 Mil).

Sino Biopharmaceutical's annual Total Liabilities increased from Dec. 2021 (HK$27,935.38 Mil) to Dec. 2022 (HK$29,169.41 Mil) but then declined from Dec. 2022 (HK$29,169.41 Mil) to Dec. 2023 (HK$27,820.12 Mil).

Sino Biopharmaceutical Total Liabilities Historical Data

The historical data trend for Sino Biopharmaceutical's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sino Biopharmaceutical Total Liabilities Chart

Sino Biopharmaceutical Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

18,864.48

29,387.92

27,935.38

29,169.41

27,820.12

Sino Biopharmaceutical Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Total Liabilities	Get a 7-Day Free Trial															27,935.38	30,699.69	29,169.41	31,918.79	27,820.12

Sino Biopharmaceutical Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Sino Biopharmaceutical's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	24726.813	+	(1501.557	+	1591.749
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	27,820

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	69569.608	-	41749.489
	=	27,820

Sino Biopharmaceutical's Total Liabilities for the quarter that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	24726.813	+	(1501.557	+	1591.749
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	27,820

Total Liabilities	=	Total Assets (Q: Dec. 2023 )	-	Total Equity (Q: Dec. 2023 )
	=	69569.608	-	41749.489
	=	27,820

Sino Biopharmaceutical Total Liabilities Related Terms

Thank you for viewing the detailed overview of Sino Biopharmaceutical's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Sino Biopharmaceutical (HKSE:01177) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sino Biopharmaceutical Ltd (HKSE:01177) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

SBHMY:USA SBMFF:USA SMZ1:Germany

Address

1 Harbour Road, Unit 09, 41st Floor, Office Tower, Room 4109, Convention Plaza, Wanchai, Hong Kong, HKG

Website

https://www.sinobiopharm.com

Sino Biopharmaceutical Co, or SBP, is one of the largest drugmakers in China, with CNY 27 billion revenue in 2021. Its four most important therapeutic areas are oncology, hepatitis, cardio-cerebral, and respiratory medicines. SBP's current portfolio is mostly generics, and some key drugs are facing severe price reductions. However, it also has a rich pipeline of early-to-market generics and biosimilars, especially in oncology and respiratory treatments.

Sino Biopharmaceutical (HKSE:01177) Headlines

No Headlines